20103 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Excipients; Inactive ingredients; Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
PHARMACEUTICAL COMPOSITION HAVING THE ACTIVE SUBSTANCES METFORMIN AND SITAGLIPTIN OR VILDAGLIPTIN
#2102Pharmaceutical compositions
#2103Pharmaceutical formulation
#2104Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
#2105Pharmaceutical formulation containing an opioid agonist, opioid antagonist and irritant agent
#2106DEFERACIROX DISPERSIBLE TABLETS
#2107Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
#2108PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#2109ORAL DOSAGE FORM FOR MODIFIED RELEASE COMPRISING A JAK3 INHIBITOR
#2110Coating film, and granules and tablets each utilizing same
#2111CO-PRECIPITATE COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5-INHIBITOR) AND A PHARMACEUTICALLY COMPATIBLE CARRIER, PRODUCTION AND USE THEREOF
#2112ORAL DOSAGE FORMS
#2113PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT
#2114N alkylcarbonyl amino lactone compounds and their use
#2115Stable dosage forms of spiro and dispiro 1,2,4-trioxolane antimalarials
#2116Co-Processed Excipient Compositions
#2117Medicaments for inhibiting thrombus formation
#2118Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
#2119Delayed release tablet with defined core geometry
#2120HIGH DRUG LOAD TABLET
#2121Delayed release tablet with defined core geometry
#2122SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME
#2123SUSTAINED RELEASE COMPOSITION OF RANOLAZINE
#2124Oxaliplatin nanoparticles and method for preparing same
#2125Diffusion-controlled dosage form and method of fabrication including three dimensional printing
#2126Slow-release cilostazol tablet having an improved elution rate and minimal side effects
#2127CELECOXIB COMPOSITIONS
#2128PHARMACEUTICAL FORMULATIONS
#2129Granulating process and thus prepared granulate
#2130Abuse resistant oral opioid formulations
#2131INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA WHICH EXHIBIT AN IN VIVO STAIR-STEPPED ABSORPTION CURVE
#2132NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2133ANTACID AND LAXATIVE TABLET
#2134Abuse resistant forms of immediate release oxycodone, method of use and method of making
#2135Implantable or insertable medical devices for controlled drug delivery
#2136Prasugrel in non-crystalline form and pharmaceutical composition thereof
#2137ALCOHOL RESISTANT DOSAGE FORMS
#2138Modified release tranexamic acid formulation
#2139Intrabuccally rapidly disintegrating tablet and a production method of the tablets
#2140Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
#2141Controlled release pharmaceutical compositions of milnacipran
#2142Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
#2143Tranexamic acid formulations
#2144DRY PROCESSING OF RETIGABINE
#2145Method for the production of bioadhesive compact matrices
#2146ATAZANAVIR FORMULATIONS
#2147MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF
#2148Aliphatic amine polymer salts for tableting
#2149TABLET CONTAINING FERRIC CITRATE
#2150PHARMACEUTICAL FORMULATIONS COMPRISING VALGANCICLOVIR
#2151Stable tablet containing 4,5-epoxymorphinan derivative
#2152Pharmaceutical composition having improved solubility
#2153IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS
#2154Pharmaceutical formulation containing gelling agent
#2155MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
#2156Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
#2157Abuse-proofed dosage form
#2158ANTIDIABETIC MEDICATIONS COMPRISING A DPP-4 INHIBITOR (LINAGLIPTIN) OPTIONALLY IN COMBINATION WITH OTHER ANTIDIABETICS
#2159ORALLY DISINTEGRATING TABLETS COMPRISING DIPHENHYDRAMINE
#2160ORAL METAXALONE COMPOSITIONS
#2161TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS
#2162Aminotetralin compounds as mu opioid receptor antagonists
#2163PHARMACEUTICAL FORMULATIONS COMPRISING DESVENLAFAXINE
#2164Extended release opioid abuse deterrent compositions and methods of making same
#2165PHARMACEUTICAL COMPOSITIONS OF ACTIVE PHARMACEUTICAL INGREDIENT COMPRISING SULPHONYLUREA MOIETY WITH EXCELLENT DISSOLUTION PROPERTIES
#2166REDUCTION OF OPIOID BLOOD FLUCTUATIONS
#2167SURFACE-TREATED MODAFINIL PARTICLES
#2168Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
#2169FORMULATIONS OF RIFAXIMIN AND USES THEREOF
#2170New Oral Formulation
#2171Melting tablet containing a sildenafil salt
#2172Method of treatment comprising administering controlled release melatonin
#2173Tamper resistant dosage form comprising an anionic polymer
#2174Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections
#2175Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
#2176Multiparticulate Controlled-Release Selective Serotonin Reuptake Inhibitor Formulations
#2177Use Of Copolymers Based On Amino-Containing Polymers As Matrix Binders In Preparing Active Compound-Containing Granules And Administration Forms
#2178GASTRORENTENTIVE ORAL HIGH DOSE ZINC PREPARATIONS
#2179Solid pharmaceutical preparations containing copolymers based on polyethers combined with poorly water-soluble polymers
#2180Pharmaceutical composition for diabetic nephropathy and its preparation and application
#2181COMPOSITION FOR ENHANCING ABSORPTION OF A DRUG AND METHOD
#2182Macrocyclic lactone drug delivery system
#2183MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS
#2184PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS
#2185Peptide pharmaceutical for oral delivery
#2186PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS
#2187METHODS FOR TREATING HYPERLIPIDEMIA WITH INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS HAVING UNIQUE BIOPHARMACEUTICAL CHARACTERISTICS
#2188TABLET FORMULATION FOR P38 INHIBITOR AND METHOD
#2189Abuse-proofed dosage form
#2190Solid Pharmaceutical Compositions Containing Pregabalin
#2191Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof
#2192Tacrolimus for improved treatment of transplant patients
#2193CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING O-DESMETHYL-VENLAFAXINE
#2194PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY
#2195Formulations of viable cells for oral delivery
#2196Pharmaceutical forms for the release of active compounds
#2197Tablet formulation of ezatiostat
#2198CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION
#2199Controlled release and taste masking oral pharmaceutical composition
#2200Modified release formulations containing drug-ion exchange resin complexes
#2201TABLET FORMULATION
#2202ADDITIONAL THERAPEUTIC USE
#2203Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
#2204ORAL CONTROLLED RELEASE DOSAGE FORMS FOR WATER SOLUBLE DRUGS
#2205Nucleotide analogue prodrug and the preparation thereof
#2206FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES
#2207DPP IV INHIBITOR FORMULATIONS
#2208Pharmaceutical Composition Comprising Aliskiren
#2209DEFERACIROX DISPERSIBLE TABLETS
#2210Once daily formulations of tetracyclines
#2211POLYMORPHS OF DARUNAVIR
#2212SOLID COMPOSITIONS
#2213Controlled release levetiracetam formulations and methods for producing the same
#2214Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
#2215PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE
#2216METHODS AND SUSTAINED RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA
#2217Modified release preparations containing oxcarbazepine and derivatives thereof
#2218HYDROMORPHONE THERAPY
#2219Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
#2220TABLET FORMULATION OF EZATIOSTAT
#2221PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID
#2222Medical item for long term drug release
#2223CONTROLLED-RELEASE PREGABALIN COMPOSITIONS
#2224Once daily formulations of tetracyclines
#2225Utilization of dialkylfumarates
#2226DIRECTLY COMPRESSIBLE GRANULAR MICROCRYSTALLINE CELLULOSE BASED, EXCIPIENT, MANUFACTURING PROCESS AND USE THEREOF
#2227Once daily formulations of tetracyclines
#2228PHARMACEUTICAL COMPOSITIONS COMPRISING ROPINIROLE
#2229CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION
#2230METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING
#2231Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
#2232Tacrolimus For Improved Treatment Of Transplant Patients
#2233Formulations of 5-fluorocytosine and uses thereof
#2234METHOD FOR PRODUCING N-VINYL PYRROLIDONE/VINYL ACETATE COPOLYMERS
#2235GABAPENTIN ENACARBIL COMPOSITIONS
#2236Solid dispersions comprising tacrolimus
#2237Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
#2238Pharmaceutical formulation for use in HIV therapy
#2239Controlled release hydrocodone formulations
#2240ORALLY DISINTEGRATING TABLET FORMULATIONS OF MIRTAZAPINE AND PROCESS FOR PREPARING THE SAME
#2241PRECOMPACTED FAST-DISINTEGRATING FORMULATIONS OF COMPOUNDS WITH A LOW ORAL BIOAVAILABILITY
#2242Opioid agonist formulations with releasable and sequestered antagonist
#2243Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
#2244Modified release compositions comprising tacrolimus
#2245Solid pharmaceutical composition comprising amlodipine and losartan
#2246Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
#2247Modified release compositions comprising tacrolimus
#2248Modified release compositions comprising tacrolimus
#2249Modified release compositions comprising tacrolimus
#2250Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
#2251Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
#2252NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2253NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2254NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2255PULSED-RELEASE SILDENAFIL COMPOSITION AND METHOD FOR PREPARING SAID COMPOSITION
#2256Stabilized formulations of CNS compounds
#2257Sustained release drug delivery system
#2258Sustained-release donepezil formulation
#2259Shell and core dosage form approaching zero-order drug release
#2260Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
#2261Tranexamic acid formulations
#2262USE OF DRONEDARONE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OF STROKE OR TRANSIENT ISCHEMIC ATTACK
#2263Pharmaceutical formulations containing opioid agonist, opioid antagonist and gelling agent
#2264ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME
#2265Extended release pharmaceutical composition of entacapone or salts thereof
#2266EXTENDED RELEASE DOSAGE FORM
#2267PHARMACEUTICAL COMPOSITION
#2268Immobilization of bioactive molecules within a polymeric substrate
#2269Flashmelt oral dosage formulation
#2270GASTRORETENTIVE ORAL HIGH DOSE ZINC PREPARATIONS
#2271CONTROLLED RELEASE ARGININE FORMULATIONS
#2272Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
#2273Composition of a 5-HTserotonin receptor modulator useful for the treatment of disorders related thereto
#2274PHARMACEUTICAL FORMULATIONS OF AN HCV PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION
#2275Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
#2276ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 MICRONS TO ABOUT 10 MICRONS
#2277DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
#2278STABLE DOSAGE FORMS OF ANTIHYPERTENSIVE AGENTS
#2279PHARMACEUTICAL COMPOUNDS AS CYTOTOXIC AGENTS AND USES THEREOF
#2280Using of organic solvents in wet granulation of moxifloxacin
#2281Controlled release arginine formulations
#2282Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
#2283Process for producing oral dosage forms with controlled release
#2284Compositions and Methods of Using (R)- Pramipexole
#2285DIAGNOSTIC REAGENT, CONTAINING BIOPARTICLES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF AS INTERNAL STANDARD IN NUCLEIC ACID PREPARATION AND NUCLEIC ACID DETECTION METHODS
#2286TELMISARTAN TABLETS
#2287BITABLETS COMPRISING COMPACTED POLYALLYLAMINE POLYMER AND METHOD FOR THE PRODUCTION THEREOF
#2288Pharmaceutical formulation
#2289Pharmaceutical compositions configured to deter dosage form splitting
#2290High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
#2291PHARMACEUTICAL DOSAGE FORM COMPRISING POLYMERIC CARRIER COMPOSITION
#2292Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation
#2293SUSTAINED RELEASE MONOEXIMIC FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS
#2294Pharmaceutical solid preparation
#2295Galenical formulations of organic compounds
#2296CONTROLLED RELEASE HYDROGEL FORMULATION
#2297DIRECTLY PRESSED ALISKIREN TABLETS
#2298PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS
#2299TREATMENT OF ADRENAL INSUFFICIENCY
#2300EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID AND PROCESS FOR PREPARING THE SAME
#2301Abuse resistant drugs, method of use and method of making
#2302Abuse resistant forms of extended release morphine, method of use and method of making
#2303Crosslinked Polymers
#2304PHARMACEUTICAL FORMULATION COMPRISING A CB1-RECEPTOR COMPOUND IN A SOLID SOLUTION AND/OR SOLID DISPERSION
#2305Method of treating dysglycemia and glucose excursions
#2306Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers
#2307Modified Release Formulation
#2308Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
#2309Abuse resistant forms of extended release hydrocodone, method of use and method of making
#2310Abuse resistant forms of extended release oxymorphone, method of use and method of making
#2311Abuse resistant forms of extended release oxycodone, method of use, and method of making
#2312Abuse resistant forms of extended release hydromorphone, method of use and method of making
#2313Controlled Release Dosage Form of Tacrolimus
#2314Solid pharmaceutical formulations comprising BIBW 2992
#2315PROCESS FOR THE PRODUCTION OF CALCIUM COMPOSITIONS IN A CONTINUOUS FLUID BED
#2316Partial dip coating of dosage forms for modified release
#2317DISSOLVABLE PHARMACEUTICAL IMPLANT
#2318Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
#2319Pharmaceutical for oral delivery comprising MGBG
#2320PHARMACEUTICAL FORMULATION
#2321Coated tablet formulations and uses thereof
#2322Oral Dosage Form Comprising Tri-Substituted Glycerol Compounds
#2323Nicotine lozenge compositions
#2324Tablet quickly disintegrating in the oral cavity and method for producing the same
#2325Moisture resistant container systems for rapidly bioavailable dosage forms
#2326GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE
#2327ONCE-A-DAY OXYCODONE FORMULATIONS
#2328Oral Pharmaceutical Compositions of Buprenorphine and Method of Use
#2329Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery
#2330Driectly Compressible High Functionality Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
#2331ORAL CALCITONIN COMPOSITIONS AND APPLICATIONS THEREOF
#2332COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF
#2333Benzonatate compositions and methods of use
#2334Methods and compositions for deterring abuse
#2335Abuse resistant drugs, method of use and method of making
#2336PROCESS FOR PREPARING SUSTAINED RELEASE TABLETS
#2337SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MEBICAR
#2338SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME
#2339Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
#2340PHARMACEUTICAL COMPOSITIONS
#2341GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF LEVOSULPIRIDE
#2342SUSTAINED RELEASE OF GUAIFENESIN
#2343GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHEN
#2344Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
#2345Orally Dissolving Formulations of Memantine
#2346Controlled Release Drug Delivery Systems And Pharmaceutical Compositions Formed Therewith
#2347DEFERACIROX DISPERSIBLE TABLETS
#2348PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF
#2349SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE
#2350SOLID PHARMACEUTICAL COMPOSITION COMPRISING IRBESARTAN
#2351MATRIX TYPE SUSTAINED-RELEASE PREPARATION CONTAINING BASIC DRUG OR SALT THEREOF AND, METHOD FOR MANUFACTURING THE SAME
#2352PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI
#2353COMPOSITIONS AND METHODS FOR TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
#2354COMPOSITE PREPARATION
#2355Controlled release hydrocodone formulations
#2356SOLID DOSAGE FORMS OF HIV PROTEASE INHIBITORS
#2357Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
#235824-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE
#2359PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF
#2360GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS
#2361Aqueous polymer dispersion based on N,N-diethylaminoethyl methacrylate, its preparation and use
#2362STABILIZED PICOPLATIN ORAL DOSAGE FORM
#2363VALSARTAN SOLID ORAL DOSAGE FORMS AND METHODS OF MAKING SUCH FORMULATIONS
#2364ORODISPERSABLE FORMULATIONS OF PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS
#2365Oral mucoadhesive dosage form
#2366VALSARTAN TABLET FORMULATIONS
#2367Antiviral drugs for treatment of arenavirus infection
#2368NOVEL DOSAGE FORM
#2369Extended release pharmaceutical compositions of levetiracetam
#2370Slow release magnesium composition and uses thereof
#2371Solid preparation comprising alogliptin and metformin hydrochloride
#2372NOVEL DOSAGE FORM
#2373Sustained release solid formulations and methods of manufacturing the same
#2374METHOD OF TREATMENT OF A NEUROLOGICAL DISORDER
#2375NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR
#2376Abuse resistant oral opioid formulations
#2377Implantable drug delivery devices and methods of making the same
#2378PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
#2379CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION
#2380Solid drug tablets for implantable drug delivery devices
#2381Gastroresistant Pharmaceutical Formulations Containing Rifaximin
#2382PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED DISSOLUTION PROFILES FOR POORLY SOLUBLE DRUGS
#2383MODIFIED RELEASE FORMULATION AND METHODS OF USE
#2384MODIFIED RELEASE FORMULATION AND METHODS OF USE
#2385Pharmaceutical solid preparation comprising benzazepines and production method thereof
#2386DISSOLVABLE PHARMACEUTICAL IMPLANT
#2387SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT
#2388Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
#2389PHARMACEUTICAL FORMULATIONS
#2390SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME
#23911-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
#2392SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF
#2393Orodispersible tablets
#2394Method to stabilize a dietary supplement to facilitate joint health in humans
#2395Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
#2396SUSTAINED RELEASE ORAL COMPOSITION OF AN ANTIPSYCHOTIC AGENT
#2397Orally Disintegrating Excipient
#2398PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE
#2399DELIVERY SYSTEM FOR POORLY SOLUBLE DRUGS
#2400Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same